Johnson & Johnson JNJ

Morningstar Rating
Add To Portfolio
$
|%
Chart Data Not Available
USD | New York Stock Exchange | Last close prices updated as of Apr 01, 2025, 4:00 PM EST | BATS BZX Real-Time Price
  • Last Close
    153
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - General
  • Investment Style
    Large Value
  • Market Cap
    369.3092 Bil
  • Forward Div Yield
    3.20%
  • Trailing Div Yield
    3.17%
  • Price/Sales
    4.29
  • Price/Book
    5.31
  • Beta (5-Year)
    0.49
  • Consensus Forward P/E
    14.47
  • Trailing 12-mo Rev
    88.82

Morningstar's Analysis

Valuation Sep 19, 2022
Currency in USD
Is it the right time to buy or sell?
Fair ValueLearn Moreplay
1-Star Price
Premium
Economic Moat
Premium
5-Star Price
Premium
Capital Allocation
Premium
Johnson & Johnson: Maintaining Our $164 Fair Value Estimate Despite New Talc Litigation Strategy
Author Photo
Karen Andersen, CFA
Director
Analyst Note | by Karen Andersen, CFA Updated Apr 01, 2025

Johnson & Johnson's third effort to settle talc claims through the bankruptcy system has failed, as a federal judge did not approve a $9 billion settlement, and the firm has decided to return to the tort system to litigate claims.

Business Strategy and Outlook | by Karen Andersen, CFA Updated Sep 27, 2024

Johnson & Johnson stands alone as a leader across the major healthcare industries. It maintains a diverse revenue base, a developing research pipeline, and exceptional cash flow generation that together create a wide economic moat.

J&J holds a leadership role in diverse healthcare segments, including medical devices and several pharmaceutical mark

Morningstar Fair Value Estimate
The Morningstar Fair Value Estimate guides investors to the long-term, intrinsic value of a stock, helping them see beyond the present market price.

Show me how fair value is derived (00:41)

Morningstar calculates the fair value estimate of a company based on a projection of how much cash the company will generate in the future. Morningstar analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. The analyst discounts future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights.

The Morningstar Fair Value Estimate is a projection/opinion and not a statement of fact. If Morningstar's base-case assumptions are true the market price will converge on Morningstar's fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in the future and is no indication of future performance.

Morningstar Equity Research Methodology

Price vs. Fair Value

 
Price/Fair Value
Total Return %
Index Total Return %
2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 YTD
1.05 15.23 24.16 -5.10 15.94 10.62 11.36 5.86 -8.61 -4.60 6.82
0.69 12.44 21.47 -5.05 31.22 20.90 25.78 -19.43 26.44 24.09 -4.63

Related

Morningstar Research
© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy       Disclosures        Accessibility